Original communication| Volume 113, ISSUE 2, P134-137, February 1993

Distribution of estrogen receptor in ductal carcinoma in situ of the breast

      This paper is only available as a PDF. To read, Please Download here.


      Background. Long-term antiestrogen therapy has been suggested as a possible treatment alternative for ductal carcinoma in situ (DCIS) of the breast. However, very little information is available on the distribution of estrogen receptor (ER) and treatment success with antiestrogen for such lesions.
      Methods. Thirty-two formalin-fixed tissue specimens of DCIS from 32 female patients aged 38 to 71 years were evaluated for the presence of ER by an immunoperoxidase technique. Antigenic sites for ER were exposed by treating the tissue sections with deoxyribonuclease followed by peroxidase-antiperoxidase staining with monoclonal antibody against ER. Parallel negative controls were run with negative control monoclonal antibody and normal rat serum. The quality control for positive staining was performed with tissue sections from specimens with known ER detected by the radioreceptor method.
      Results. Eighteen (60%) of the 32 lesions were positive for ER. In 7 of the 18 lesions less than 25% of cells stained positive for ER and in 4 of the 18 more than 50% of cells stained positive for ER.
      Conclusions. The incidence of ER in DCIS is similar to the incidence of ER in invasive carcinoma, leading to the speculation that ER-positive invasive carcinoma originates from an ER-positive precursor lesion. Because only 60% of the cases have detectable ER and approximately 70% of positively stained ERs are expected to be functional (as in invasive carcinoma), it appears that approximately 42% of the patient population with DCIS will benefit from antiestrogen therapy.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Surgery
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Baker LH
        Breast cancer detection demonstration project: five-year summary report.
        Cancer. 1982; 32: 194-225
        • Lemanne D
        • Simon M
        • Martino S
        • Swanson M
        Breast carcinoma in situ (CIS): greater rise in ductal carcinoma in situ (DCIS) vs lobular carcinoma in situ (LCIS) [Abstract].
        in: 2nd ed. Proc Am Soc Clin Oncol. 10. 1991: 45
        • Holland R
        • Hendricks JHCL
        • Verbeek ALM
        • Mravunac M
        • Schuurman S
        • Stekhovan JH
        Extent of distribution and mammographic histologic correlation of breast ductal carcinoma in situ.
        Lancet. 1991; 335: 519-522
        • Bestill WL
        • Rosen PP
        • Liebaman PH
        • Robin GF
        Intraductal carcinoma; longterm follow-up after treatment by biopsy alone.
        J Am Med Assoc. 1978; 239: 1863-1867
        • Page DL
        • Dupont WD
        • Rogers LW
        • Landenberger M
        Intraductal carcinoma of breast: follow-up after biopsy only.
        Cancer. 1982; 49: 751-758
        • Rosen PP
        • Barun Jr, DW
        • Kinne DE
        The clinical significance of preinvasive breast carcinoma.
        Cancer. 1980; 46: 909-925
        • Schmitt ST
        • Silen N
        • Sadowsky NL
        • Connolly JL
        • Harris JR
        Ductal carcinoma in situ (intraductal carcinoma) of the breast.
        N Engl J Med. 1988; 318: 898-903
        • Tinnemans JGM
        • Wobbes T
        • Holland R
        • Hendriks J
        • VanDersutes RF
        • Debder HHM
        Treatment and survival of female patients with non-palpable breast cancer.
        Ann Surg. 1989; 209: 245-253
        • Graversen HP
        • Blicert-Toft M
        • Dyreborg U
        • Anderson J
        In situ carcinoma of the female breast: incidence, clinical finding and DBCA proposal for management.
        Acta Oncol. 1988; 27: 679-682
        • Recht A
        • Solin LJ
        • Kurtz JM
        • et al.
        Conservative surgery and radiotherapy (CS and RT) for ductal carcinoma in situ (DCIS) [Abstract].
        in: 2nd ed. Proc Am Soc Clin Oncol. 10. 1991: 47
        • Buzdar AU
        Future direction of adjuvant and preventive therapy of breast cancer.
        Rev Endocr Rel Cancer. 1987; 27: 11-15
        • Cuzick J
        • Wang DY
        • Bulbrook RO
        The prevention of breast cancer.
        Lancet. 1986; 2: 83-86
        • Jordan VC
        The control of hormone dependent breast cancer growth: are we talking about estrogen alone?.
        Eur J Cancer Clin Oncol. 1988; 24: 1245-1248
        • Shintaku LP
        • Said JR
        Detection of estrogen receptors with monoclonal antibodies in routinely processed formalin fixed paraffin sections of breast carcinoma.
        Am J Clin Pathol. 1987; 87: 161-167
        • Hellman J
        • Harris JR
        • Camellos GP
        • Fisher B
        Cancer of the breast.
        in: DeVita VT Hellman S Rosenberg SA Cancer principles and practice of oncology. JB Lippincott, Philadelphia1982: 914-970
        • Morgan Jr, LR
        • Schein PS
        • Wooley PV
        • et al.
        Therapeutic use of tamoxifen in advanced breast cancer: correlation with biochemical parameters.
        Cancer Treat Rep. 1976; 60: 1437-1443
        • Masood S
        Use of monoclonal antibody for assessment of estrogen receptor content in fine needle aspiration biopsy specimen from patients with breast cancer.
        Arch Pathol Lab Med. 1989; 113: 26-30
        • Barnes R
        • Masood S
        Potential value of hormone receptor assay in carcinoma in situ of breast.
        Am J Clin Pathol. 1990; 94: 533-537
        • McGuire WL
        • Horwitz KB
        • Zava DT
        • et al.
        Hormones in breast carcinoma.
        Metabolism. 1978; 27: 487-501
        • Paul FF
        • Wagner RK
        The histopathologist evaluation of human breast cancers in correlation with estrogen receptor value.
        Cancer. 1980; 46: 362-387
        • Kiang DT
        • Kennedy BJ
        Tamoxifen (antiestrogen) therapy in advanced breast cancer.
        Ann Intern Med. 1977; 87: 687-690
        • Henry JA
        • McCarthy AL
        • Angus B
        • Westley BR
        • et al.
        Prognostic significance of estrogen regulated protein, cathepsin D, in breast cancer.
        Cancer. 1990; 65: 265-271